Moleculin Biotech Q1 EPS $(0.28) Misses $(0.25) Estimate, Cash at Q1 $37.3M - Sufficient Capital To Fund Operations Till 3Q24

Benzinga · 05/11/2023 07:12
Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.25) by 12 percent. This is a 16.67 percent decrease over losses of $(0.24) per share from the same period last year.